Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566853 | 1.00 | MCL1 (0.57) | MCL1ALDH1A1HPGDIKBKBBCL2L1 | |
| SCHEMBL17934622 | 0.92 | ALDH1A1 (0.60) | MCL1ALDH1A1HPGDMYC | |
| SCHEMBL4215334 | 0.83 | KDM4E (0.55) | IKBKBAKR1B1ENPP2 | |
| SCHEMBL4828044 | 0.83 | KDM4E (0.55) | IKBKBAKR1B1ENPP2 | |
| SCHEMBL1102002 | 0.78 | ALDH1A1 (0.70) | MCL1ALDH1A1HPGDMYC | |
| SCHEMBL17934604 | 0.76 | MYC (0.59) | MCL1ALDH1A1HPGDMYC | |
| SCHEMBL4207906 | 0.75 | AKR1B1 (0.59) | MCL1HPGDAKR1B1ENPP2 | |
| SCHEMBL2172867 | 0.75 | MCL1 (0.44) | MCL1ALDH1A1HPGD | |
| SCHEMBL4207901 | 0.75 | AKR1B1 (0.59) | MCL1HPGDAKR1B1ENPP2 | |
| SCHEMBL4209066 | 0.75 | MAPK1 (0.55) | MCL1IKBKBAKR1B1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348348-B2 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK & CO. INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | KCNN1, KCNH1, KCNN2 | MCL1 1647/4885ALDH1A1 993/4885HPGD 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.